Pricing Log in Create free account
Saturday 17 October 2026 Export RVTY’s income statement to Excel — free account

Revvity Inc.

RVTY Healthcare Diagnostics & Research

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024. In the quarter to June 2026, revenue grew 1.31%, EPS grew 2.17%, free cash flow grew 59.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

152.64 2.07 −1.34%
Market cap
$17.3B
P/E
72.7×
Fwd P/E
37.5×
Dividend yield
0.23%
F-score
6/9
Altman Z
2.49
Beneish M
−2.45
Dividend safety
80/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Revvity Inc. (RVTY) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Revvity Inc. (RVTY) trades at a EV/EBITDA of 24.8×. Over the past ten years it has ranged from 10.5× (May 2021) to 27.0× (September 2018); the current reading is higher than 97% of that period. That is in line with the Diagnostics & Research industry median of 24.3× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 17.7× (11.87%)
FY2024 20.1× (7.49%)
FY2023 21.7× 22.10%
FY2022 17.8× 3.27%
FY2021 17.2× 5.19%
FY2020 16.4× (22.10%)
FY2019 21.0× 6.41%
FY2018 19.8× (18.50%)
FY2017 24.2× 48.34%
FY2016 16.3× (12.30%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 18.8× 20.50%
Mar 2026 15.6× (11.83%)
Dec 2025 17.7× 10.77%
Sep 2025 16.0× (6.15%)
42 more quarters

Against its own ten years

Low 10.5× High 27.0×
Ten-year median 19.5×
Current reading's percentile 97

EV/EBITDA against peers

Company EV/EBITDA
TWST Twist Bioscience Corporation compare n/m
GH Guardant Health, Inc. compare n/m
DGX Quest Diagnostics Incorporated compare 14.1×
LH Labcorp Holdings Inc. compare 14.5×
QGEN QIAGEN N.V. compare 15.9×
ICLR ICON PLC compare 23.3×
RVTY Revvity Inc. 24.8×
MEDP Medpace Holdings, Inc. compare 27.9×
CRL Charles River Laboratories International, Inc. compare 30.4×
Diagnostics & Research industry median 24.3×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on RVTY